Clinical Trial to Evaluate the Safety and Efficacy of Scarclinic™ Thin in Surgical Scars
NCT ID: NCT01689857
Last Updated: 2013-04-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2010-10-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participant: 40 Treatment period : 3 months Medical device: Scarclinic™Thin , Scarclinic™ Normal Randomization: Table of random number
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
NCT02985151
Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars
NCT06138964
Sculptra for Décolletage Crepiness and Wrinkling
NCT03508973
Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
NCT06210919
The Efficacy of Combination Therapy in Atrophic Scars
NCT06298591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* The investigator check Vancouver Scar Scale at 1 and 3 month after application to evaluate vascularity, pigmentation, elasticity, height, pain and itchiness
* The participant filled out survey included questions regarding convenience in use at 1 and 3 month after application.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Scarclinic™ Thin
Scarclinic™ Thin
Scarclinic™ Thin
Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
Scarclinic™ Normal
Scarclinic™ Normal
Scarclinic™ Normal
Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Scarclinic™ Thin
Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
Scarclinic™ Normal
Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who has a surgical scar that is not over 3 months after the surgery
* Patient who sign informed consent form for the study
Exclusion Criteria
* wound infection
* general malaise
* history of mental disorders
* taking anticancer drugs or antiphlogistics or steroid
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chan-Yeong Heo
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ChanYoung Heo, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National Univ. Bundang Hospital
Bundang-gu, Seongnam-si,Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-2010-049
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
E-1004-048-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.